Pfizer

News

Reuters - 2 hours ago

Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say

EXCLUSIVE-Vista, Blackstone nearing $8-billion deal to buy Smartsheet, sources say By Milana Vinn and Mike Spector NEW YORK, Sept 16 (Reuters) - Buyout firms Vista Equity Partners and Blackstone BX.N are in advanced talks to acquire Smartsheet SMAR.N , in a deal that could value the collaboration-software maker at close to $8 billion, people familiar with the matter said on Monday.

Reuters - 4 hours ago

U.S. STOCKS Charles Schwab, CACI International, Icahn Enterprises

BUZZ-U.S. STOCKS ON THE MOVE-Charles Schwab, CACI International, Icahn Enterprises Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Technology stocks weighed on the S&P 500 and the Nasdaq on Monday as caution set in ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep reduction in borrowing costs.

Reuters - 6 hours ago

U.S. STOCKS Bausch + Lomb, Alcoa, crypto stocks

BUZZ-U.S. STOCKS ON THE MOVE-Bausch + Lomb, Alcoa, crypto stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The main U.S. stock indexes were set for a mixed open on Monday as caution set in on Wall Street ahead of the Federal Reserve's pivotal monetary policy decision, due later in the week, with a majority of traders pricing in a steep cut in borrowing costs.

Reuters - 8 hours ago

U.S. STOCKS Intel, Colgate-Palmolive, Zillow Group

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Colgate-Palmolive, Zillow Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were subdued on Monday as caution prevailed ahead of the Federal Reserve's pivotal monetary policy decision later in the week, with investors pricing in a steep reduction in borrowing costs.

Reuters - 9 hours ago

Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says

BUZZ-Pfizer's mid-stage cancer drug data at ESMO 'intriguing', Guggenheim says ** Brokerage Guggenheim notes mid-stage data for Pfizer's PFE.N ponsegromab in cancer cachexia to be "intriguing"; says could lead to increased investor interest ahead of mid-stage data in heart failure expected next year ** PFE at the European Society for Medical Oncolo

Reuters - 2 days ago

Pfizer Presents Positive Data From Phase 2 Study Of Ponsegromab In Patients With Cancer Cachexia

BRIEF-Pfizer Presents Positive Data From Phase 2 Study Of Ponsegromab In Patients With Cancer Cachexia Sept 14 (Reuters) - Pfizer Inc PFE.N : PFIZER PRESENTS POSITIVE DATA FROM PHASE 2 STUDY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA PFIZER - STUDY MET PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN BODY WEIGHT FOR PONSEGROMAB COMPARED TO PLACEBO

Reuters - 3 days ago

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi By Michael Erman NEW YORK, Sept 14 (Reuters) - Pfizer PFE.N is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care. The company presented three-year follow-up data from a Phase 2 study on Saturday looking at patients with BRAF V600E-mutant metastatic non-small cell l

Reuters - 3 days ago

US FDA approves Eli Lilly's drug for eczema

UPDATE 2-US FDA approves Eli Lilly's drug for eczema Adds details on disease in paragraph 3, patient population in paragraph 6, other treatments in paragraphs 7-8, details on drug in paragraphs 8-9 Sept 13 (Reuters) - Eli Lilly LLY.N said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.

Reuters - 4 days ago

Roche shares knocked by concern over side effects in obesity pill trial

UPDATE 1-Roche shares knocked by concern over side effects in obesity pill trial Roche shares fall 3.5% Early study trial showed high rate of temporary side effects JP Morgan analysts say heart rate increase is as a concern Roche plans slower ramp-up of pill dose in next trial Updates share price in paragraph 2, further details on side effects in pill trial in paragraphs 6 and 8 FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S dropped to a two-month low on Thursday after an experimental weig

Reuters - 4 days ago

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial By Kashish Tandon Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.

Reuters - 4 days ago

Moderna forecasts lower sales next year, shares slide to four-year low

UPDATE 4-Moderna forecasts lower sales next year, shares near four-year low Adds executive comment in paragraph 7 By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year, sending its shares closer to a four-year low.

Reuters - 4 days ago

Moderna expects up to $3.5 billion in 2025 sales

Moderna expects up to $3.5 billion in 2025 sales By Patrick Wingrove Sept 12 (Reuters) - Moderna MRNA.O on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028. The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual revenue since Moderna launched its COVID-19 vaccine in late 2020

Reuters - 5 days ago

Roche shares drop on side effects result in early-stage obesity pill trial

Roche shares drop on side effects result in early-stage obesity pill trial FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial .

Reuters - 5 days ago

Roche says early-stage obesity pill results were based on just six patients

UPDATE 1-Roche says early-stage obesity pill results were based on just six patients Adds detail of trial in paragraph 6, company comment in paragraph 7, further detail in paragraphs 8-10 FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.

Reuters - 5 days ago

Roche says early-stage obesity pill results were based on just six patients

Roche says early-stage obesity pill results were based on just six patients FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project. The Swiss drugmaker said in July that the once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patie

Reuters - 6 days ago

Weight-loss market to see 16 new drugs by 2029, report estimates

Weight-loss market to see 16 new drugs by 2029, report estimates Sept 10 (Reuters) - The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N , according to estimates from analysts at Morningstar and Pitchbook. In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031. The 16 drugs could launch by 2029, wi

Reuters - 6 days ago

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.

Reuters - 6 days ago

Ireland can use unwanted taxes to keep Apple sweet

BREAKINGVIEWS-Ireland can use unwanted taxes to keep Apple sweet The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 10 (Reuters Breakingviews) - Big Tech taxes are not the Apple AAPL.O of Ireland’s eye. That is the message Dublin sent when it sided with the iPhone maker in a European Union dispute over 13 billion euros in corporate levies.

Reuters - 6 days ago

Trump’s super-tariff is dangerously simple

RPT-BREAKINGVIEWS-Trump’s super-tariff is dangerously simple The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By John Foley NEW YORK, Sept 9 (Reuters Breakingviews) - Earlier this year, libertarian think tank the Cato Institute surveyed Americans to see if they thought tariffs on imported blue jeans would be a good idea.

Reuters - 1 week ago

Big Pharma lacks motive to prep for new pandemics

BREAKINGVIEWS-Big Pharma lacks motive to prep for new pandemics The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 10 (Reuters Breakingviews) - Covid-19 underlined the critical importance of vaccines. The pandemic caused 16 million global deaths, and the current scare surrounding Mpox emphasises how citizens remain fearful of fresh outbreaks.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Pfizer

News

Conditions

Popular Assets

XM Live Chat